Literature DB >> 34230977

Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Susan J Robertson1, Elizabeth Orrin, Manpreet K Lakhan, Gavin O'Sullivan, Jessie Felton, Alistair Robson, Danielle T Greenblatt, Catina Bernardis, John A McGrath, Anna E Martinez, Jemima E Mellerio.   

Abstract

Epidermolysis bullosa (EB), notably severe recessive dystrophic EB (RDEB-S), is associated with increased risk of aggressive mucocutaneous squamous cell carcinomas, the major cause of mortality in early adulthood. This observational, retrospective case review describes a series of EB patients with cutaneous squamous cell carcinomas over a 28-year period. Forty-four EB patients with squamous cell carcinomas were identified with a total of 221 primary tumours. They comprised: 31 (70%) with RDEB-S, 4 (9%) with other RDEB subtypes, 5 (11.4%) with dominant dystrophic EB, 3 (6.8%) with intermediate junctional EB and 1 (2.3%) with Kindler EB. Squamous cell carcinomas occurred earlier in RDEB-S (median age 29.5 years; age range 13-52 years) than other groups collectively (median age 47.1 years; age range 30-89 years) and most had multiple tumours (mean 5.8; range 1-44). Squamous cell carcinoma-associated mortality was high in RDEB-S (64.5%), with median survival after first squamous cell carcinoma of 2.4 years (range 0.5-12.6 years), significantly lower than previous reports, highlighting the need for early surveillance and better treatments.

Entities:  

Keywords:  cancer; prognosis; squamous cell carcinoma; epidermolysis bullosa

Mesh:

Year:  2021        PMID: 34230977      PMCID: PMC9413672          DOI: 10.2340/00015555-3875

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  37 in total

Review 1.  Topical photodynamic therapy for Bowen's disease of the digit in epidermolysis bullosa.

Authors:  C S Souza; L B A Felício; M V Bentley; A C Tedesco; J Ferreira; C Kurachi; V S Bagnato
Journal:  Br J Dermatol       Date:  2005-09       Impact factor: 9.302

2.  Dystrophic epidermolysis bullosa. Tolerance of the bed and response of multifocal squamous cell carcinomas to ionizing radiation: report of a case.

Authors:  R W Edland
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1969-03

3.  Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.

Authors:  Joanna Jacków; Avina Rami; Ryota Hayashi; Corey Hansen; Zongyou Guo; Dominick DeLorenzo; Alberto Pappalardo; David Alvarez Cespedes; Arianna L Kim; Rolando Perez-Lorenzo; David M Owens; Angela M Christiano
Journal:  J Invest Dermatol       Date:  2020-10-16       Impact factor: 8.551

4.  Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.

Authors:  Velina S Atanasova; Celine Pourreyron; Mehdi Farshchian; Michael Lawler; Christian A Brown; Stephen A Watt; Sheila Wright; Michael Warkala; Christina Guttmann-Gruber; Josefina Piñón Hofbauer; Ignacia Fuentes; Marco Prisco; Elham Rashidghamat; Cristina Has; Julio C Salas-Alanis; Francis Palisson; Alain Hovnanian; John A McGrath; Jemima E Mellerio; Johann W Bauer; Andrew P South
Journal:  Clin Cancer Res       Date:  2019-03-07       Impact factor: 12.531

Review 5.  Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: case reports and literature review.

Authors:  K T Bastin; R A Steeves; M J Richards
Journal:  Am J Clin Oncol       Date:  1997-02       Impact factor: 2.339

6.  Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain.

Authors:  B Castelo; D Viñal; R Maseda; L Ostios; D Sánchez; B García-Salvatierra; M J Escámez; L Martínez-Santamaría; M Del Río; M Mora-Rillo; Y Vilches; M J Beato; J C López Gutiérrez; N Romero; C Santos; J Miranda; R de Lucas
Journal:  Clin Transl Oncol       Date:  2019-03-12       Impact factor: 3.405

7.  Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand.

Authors:  Minhee Kim; Minmin Li; Lizbeth R A Intong-Wheeler; Kim Tran; Damian Marucci; Dedee F Murrell
Journal:  Acta Derm Venereol       Date:  2018-01-12       Impact factor: 4.437

Review 8.  Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines.

Authors:  J E Mellerio; S J Robertson; C Bernardis; A Diem; J D Fine; R George; D Goldberg; G B Halmos; M Harries; M F Jonkman; A Lucky; A E Martinez; E Maubec; S Morris; D F Murrell; F Palisson; E I Pillay; A Robson; J C Salas-Alanis; J A McGrath
Journal:  Br J Dermatol       Date:  2015-11-07       Impact factor: 9.302

Review 9.  Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases.

Authors:  H Montaudié; C Chiaverini; E Sbidian; A Charlesworth; J-P Lacour
Journal:  Orphanet J Rare Dis       Date:  2016-08-20       Impact factor: 4.123

10.  Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Karam Khaddour; Emily S Gorell; Farrokh Dehdashti; Jean Y Tang; George Ansstas
Journal:  Case Rep Oncol       Date:  2020-07-30
View more
  2 in total

Review 1.  Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.

Authors:  Domenico Bonamonte; Angela Filoni; Aurora De Marco; Lucia Lospalluti; Eleonora Nacchiero; Valentina Ronghi; Anna Colagrande; Giuseppe Giudice; Gerardo Cazzato
Journal:  Cells       Date:  2022-04-17       Impact factor: 7.666

2.  Identification of a novel homozygous LAMB3 mutation in a Chinese male with junctional epidermolysis bullosa and severe urethra stenosis: A case report.

Authors:  Wei Wang; Qiang Guo; Jinshan Chen; Xi Zhang; Chengyong Li; Shuangping Li; Jialin Liang; Chuan Hao; Jingqi Wang
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.